

VIII Convegno Nazionale Fondazione AMD



PALERMO, 17-19 NOVEMBRE 2016

Anno: 2015 2017 Gruppo Intersocietario AMD-OSDI Terapia Iniettiva


Coordinatore del Gruppo: Sandro Gentile

*Componenti: Katja Speese (OSDI), Lia Cucco (OSDI), Maria Teresa Branca, (OSDI),
Laura Tonutti, Nicoletta De Rosa, Stefano De Riu, Giorgio Grassi*

Referente per il CDN: Amodio Botta

Mandato del CDN:

Migliorare Appropriatazza e Competence del diabetologo, del team diabetologico e degli altri stakeholders sulle tecniche iniettive, sulle modalità prescrittive, di dispensazione, manipolazione e conservazione dell'insulina, nonché sul rischio di punture accidentali nei vari setting assistenziali, per ottimizzare compenso metabolico e qualità di vita dei diabetici in terapia iniettiva e per razionalizzare i costi.



Laura Tonutti




Giorgio Grassi



Nicoletta De Rosa



Sandro Gentile



Lia Cucco



M T Branca



Katja Speese



Stefano De Riu

Documenti
Di consenso

Book Chapter

INJECTION-RELATED LOCAL SIDE EFFECTS IN THE TREATMENT OF DIABETES MELLITUS: a methodological approach and possible solutions.
Consensus Statement of AMD-OSDI Study Group on Injection Technique.

Gentile Sandro (MD Prof)¹, Strollo Felice (MD Prof)², De Rosa Nicoletta (MD)³, Grassi Giorgio (MD)⁴, Lalli Carlo (MD)⁵, Lo Grasso Giovanni (HN)⁶, Marcone Teresa Anna Maria (MD)⁷, Sudano Maurizio (MD)⁸, Gentile Luigi (MD)⁹, Giancaterini Annalisa (MD)¹⁰, Tatti Patrizio (MD Prof)¹¹, Tonutti Laura (MD)¹², Guarino Giuseppina (MD Prof)¹³, Armentano Vincenzo (MD)¹⁴, Chiandetti Roberta (HN)¹⁵, Garapa Gabriella (MD)¹⁶, De Riu Stefano (MD)¹⁷, Cucco Lia (HN)¹⁸, Speese Katja (HN)¹⁹, Botta Amedeo (MD)¹⁸

Documento di Consenso su Gestione e Utilizzo dei Sistemi Iniettivi dell'insulina in Ospedale
in collaborazione con
Gruppo Inter-Societario AMD-OSDI sulle Tecniche Iniettive

Coordinatore Sandro Gentile (AMD)

Vincenzo Armentano (AMD), Lia Cucco (OSDI), Nicoletta De Rosa (AMD), Luigi Gentile (AMD), Annalisa Giancaterini (AMD), Giorgio Grassi (AMD), Carlo Lalli (AMD), Giovanni Lo Grasso (OSDI), Teresa Anna Maria Marcone (AMD), Maurizio Sudano (AMD), Patrizio Tatti (AMD), Laura Tonutti (AMD)

AMD-OSDI CONSENSUS ON INJECTION TECHNIQUES FOR PEOPLE WITH DIABETES MELLITUS

Sandro Gentile (MD, Prof)¹, Giorgio Grassi (MD)², Vincenzo Armentano (MD)³, Amedeo Botta (MD)⁴, Lia Cucco (HN)⁵, Stefano De Riu (MD)⁶, Nicoletta De Rosa (MD)⁷, Gabriella Garapa (MD)⁸, Luigi Gentile (MD)⁹, Annalisa Giancaterini (MD)¹⁰, Carlo Lalli (MD)¹¹, Giovanni Lo Grasso (HN)¹², Teresa Anna Maria Marcone (MD)¹³, Chiandetti Roberta (HN)¹⁴, Katja Speese (HN)¹⁵, Maurizio Sudano (MD)¹⁶, Patrizio Tatti (MD, Prof)¹⁷, Laura Tonutti (MD)¹⁸, Maria Teresa Branca (HN)¹⁹ and Felice Strollo (MD, Prof)²⁰

Documenti di Consenso

Raccomandazioni per una corretta tecnica iniettiva e per la prevenzione delle lipodistrofie e del rischio di punture accidentali

Tavolo di lavoro AMD-OSDI-SID

Sandro Gentile, Annalisa Giancaterini (AMD), Lia Cucco, Giovanni Lo Grasso (OSDI), Francesco Porcellini, Luigi Gentile (SID)
© Giornale di AMD, 2015, 18-208-217

AMD **SID**

Standard italiani per la cura del diabete mellito 2016

Questo testo è disponibile, in forma elettronica e interattiva, presso il website di riferimento: www.standarditaliani.it, raggiungibile anche dal website di AMD e SID

Data di nascita: 20 giugno 2016

G. TECNICHE INIETTIVE
RACCOMANDAZIONI (pag 117-124)

Insulin treatment

AMD Algorithm on Correct Injection Technique

Attività
scientifica

AMD-OSDI Consensus on Injection Techniques for People with Diabetes Mellitus

Abstract

Background: The aim of this study was to develop a consensus on injection techniques for people with diabetes mellitus (DM) to improve the quality of care and reduce the risk of complications.

Methods: A panel of experts in the field of diabetes mellitus and injection techniques was convened to discuss and develop a consensus on injection techniques for people with DM.

Results: The consensus includes recommendations on the use of insulin, the choice of injection site, the use of insulin pens, and the use of insulin pumps.

Conclusions: The consensus provides a comprehensive guide to injection techniques for people with DM, covering all aspects of the process from the choice of insulin to the use of insulin pumps.

SUBSTITUTABLES NEEDED DURING TREATMENT WITH EXACTIVE LONG-ACTING GLICED-WHERE FORMULATION: A SUBSTITUTABLES EVALUATION


Abstract

Background: The aim of this study was to evaluate the substitutability of Exactive long-acting glimed-where formulation with other long-acting glimed-where formulations during treatment.

Methods: A panel of experts in the field of diabetes mellitus and long-acting glimed-where formulations was convened to discuss and evaluate the substitutability of Exactive with other long-acting glimed-where formulations.

Results: The study found that Exactive is substitutable with other long-acting glimed-where formulations during treatment.

Conclusions: The study provides evidence that Exactive is a substitutable long-acting glimed-where formulation.



Il «spazio» della terapia insulinica tra ospedale e territorio: contributo normativo

Abstract

Background: The aim of this study was to analyze the normative framework governing the use of insulin therapy in the hospital and territorial settings.

Methods: A panel of experts in the field of diabetes mellitus and insulin therapy was convened to discuss and analyze the normative framework.

Results: The study found that the normative framework governing the use of insulin therapy is complex and involves multiple stakeholders.

Conclusions: The study provides a comprehensive overview of the normative framework governing the use of insulin therapy in the hospital and territorial settings.

Diabetologia
DOI 10.1007/s00143-016-0874-6

Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?

Sandro Gentile · Felice Strollo · Antonio Ceriello

On behalf of the AMD-OSDI Injection Technique Study Group

Int J Endocrinol Metab. In Press (2016) doi:10.5832/ijem.13997

Published online 2016 April 26. Article Commentary

Lipodystrophy and Associated Risk Factors in Insulin-Treated People With Diabetes

Sandro Gentile¹, Felice Strollo^{1,2} and Antonio Ceriello^{1,4}

DIABETES RESEARCH

Open Journal

Unexplained Hypoglycaemia and Large Glycaemic Variability: Skin Lipohypertrophy as a Predictive Sign

Felice Strollo, MD, Prof.¹; Giuseppina Guarino, MD¹; Vincenzo Armentano, MD¹; Gennaro Clemente, MD¹; Emilia Martelli, MD¹; Stefano de Riu, MD¹; Iole Gaeta, MD¹; Gerardo Corigliano, MD¹; Antonio Ceriello, MD, Prof.¹; Sandro Gentile, MD, Prof.¹ on behalf of AMD-OSDI Italian Study Group on Injection Techniques

Factors Hindering Correct Identification of Unapparent Lipohypertrophy

Abstract

Background: The aim of this study was to identify factors that hinder the correct identification of unapparent lipohypertrophy.

Methods: A panel of experts in the field of diabetes mellitus and lipohypertrophy was convened to discuss and identify factors that hinder the correct identification of unapparent lipohypertrophy.

Results: The study found that several factors hinder the correct identification of unapparent lipohypertrophy, including the use of insulin pens and the use of insulin pumps.

Conclusions: The study provides a comprehensive overview of factors that hinder the correct identification of unapparent lipohypertrophy.

Insulin Shot Dependent Lipodystrophy: Evidence, Uncertainties and Current Terminology Overlaps

Abstract

Background: The aim of this study was to analyze the evidence, uncertainties, and current terminology overlaps related to insulin shot dependent lipodystrophy.

Methods: A panel of experts in the field of diabetes mellitus and lipodystrophy was convened to discuss and analyze the evidence, uncertainties, and current terminology overlaps.

Results: The study found that there is significant evidence, uncertainty, and current terminology overlaps related to insulin shot dependent lipodystrophy.

Conclusions: The study provides a comprehensive overview of the evidence, uncertainties, and current terminology overlaps related to insulin shot dependent lipodystrophy.

Factors Hindering Correct Identification of Unapparent Lipohypertrophy

Abstract

Background: The aim of this study was to identify factors that hinder the correct identification of unapparent lipohypertrophy.

Methods: A panel of experts in the field of diabetes mellitus and lipohypertrophy was convened to discuss and identify factors that hinder the correct identification of unapparent lipohypertrophy.

Results: The study found that several factors hinder the correct identification of unapparent lipohypertrophy, including the use of insulin pens and the use of insulin pumps.

Conclusions: The study provides a comprehensive overview of factors that hinder the correct identification of unapparent lipohypertrophy.

Attività di formazione



Federfarma ONLUS
Associazione Nazionale dei Farmaci e Farmacisti di Base e Farmacie

AMD
Associazione Nazionale dei Medici di Famiglia e Generalisti

IL DIABETE IN FARMACIA TRA DISPOSITIVI MEDICI INNOVATIVI, AUTOCONTROLLO GLICEMICO E CORRETTE INDICAZIONI PER L'INIEZIONE INSULINICA

VENERDI' 21 OTTOBRE 2016, ORE 09,00
Sala Congressi di Palermo
Via Trabucchi, 10 Roma, 00186

Organizzatore e buffer di contenuti:
Associazione del Centro e cura del Mediatore
Relatore: Dr. A. SERRAVALLE, UOMO MEDICO SARTANO DEL TERRITORIO E RUOLO DEL FARMACISTA, COME INTERLOCUTORE PROVOCATO DEL DIABETICO E PARTE INTEGRANTE DEL TEAM DI CURA ALL'AMBITO.
Relatore: Dr. AUTOCONTROLLO GLICEMICO: strumenti innovativi e norme IAO, educazione all'autocontrollo, collaborazione Farmacia + Diabetologo.
Relatore: Dr. LA CURA DEL DIABETICO MEDIO-ALTO.
Dr. Teodoro GRIFFIO, Dr. Giuseppe GROSSI, Daniela GROSSI, Maria Teresa GROSSI.

Discussione Generale
Relatori: Enzo Leo Carlo GUO, Territorio Ospedale di Palermo e Osp. Roberto di Agrigoro (Assistente SO di Gastroenterologia, Endocrinologia, Malattie Metaboliche, POI "Vida Sweet" ASL Catania).
Moderatore: Carlo Sergio Leone, (Farmacista SO Endocrinologia, Ospedale Santa Maria, Roma).
Destinatari: Medici di Farmacia
Conti per Farmacia (adesso grazie ad un contributo straordinario dal comitato di Agrigoro).

federfarma napoli
Associazione Nazionale dei Farmaci e Farmacie di Napoli

AMD
Associazione Nazionale dei Medici di Famiglia e Generalisti

IL DIABETE IN FARMACIA TRA DISPOSITIVI MEDICI INNOVATIVI, AUTOCONTROLLO GLICEMICO E CORRETTE INDICAZIONI PER L'INIEZIONE INSULINICA

VENERDI' 21 OTTOBRE 2016, ORE 09,00
Sala di Conferenze
Via Toledo, 100 - 00186 Napoli

Organizzatore e buffer di contenuti:
Associazione del Centro e cura del Mediatore
Relatore: Dr. A. SERRAVALLE, UOMO MEDICO SARTANO DEL TERRITORIO E RUOLO DEL FARMACISTA, COME INTERLOCUTORE PROVOCATO DEL DIABETICO E PARTE INTEGRANTE DEL TEAM DI CURA ALL'AMBITO.
Relatore: Dr. AUTOCONTROLLO GLICEMICO: strumenti innovativi e norme IAO, educazione all'autocontrollo, collaborazione Farmacia + Diabetologo.
Relatore: Dr. LA CURA DEL DIABETICO MEDIO-ALTO.
Dr. Teodoro GRIFFIO, Dr. Giuseppe GROSSI, Daniela GROSSI, Maria Teresa GROSSI.

Discussione Generale
Relatori: Enzo Leo Carlo GUO, Territorio Ospedale di Palermo e Osp. Roberto di Agrigoro (Assistente SO di Gastroenterologia, Endocrinologia, Malattie Metaboliche, POI "Vida Sweet" ASL Catania).
Moderatore: Carlo Sergio Leone, (Farmacista SO Endocrinologia, Ospedale Santa Maria, Roma).
Destinatari: Medici di Farmacia
Conti per Farmacia (adesso grazie ad un contributo straordinario dal comitato di Agrigoro).

**Buon lavoro e
buon congresso a tutti**

